× Industry Reports Services Press Release Contact us About us

Asia Pacific Regenerative Medicine Market Forecast 2027 By Application (Oncology, Dermatology, Musculoskeletal, Neurology, Cardiovascular, Wound Healing, Ophthalmology), By Type (Cell therapy, Tissue Engineering, Gene Therapy), Research Report, Country Outlook (Japan, China, India, South Korea, Australia, Taiwan, New Zealand, Singapore, Philippines), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share
Published Date: October 2021 | Publisher: Graphical Research Report ID: GR1980 | Delivery : PDF  Request Free Sample

Asia Pacific Regenerative Medicine Market size was over USD 5 billion in 2020 and is projected to observe around 20.8% growth rate between 2021 and 2027.

Regenerative medicine is field of medicinal science that aims at development of products to repair or restore functions of damaged tissues, cells, and organs. It provides advanced therapies for range of diseases with the help of stem cells and tissue engineering.

Asia Pacific Regenrative Medicine Market Size

Get more details on this report - Request Free Sample PDF

Increasing adoption of stem cell technology for the treatment of various health conditions will augment the market revenue. Stem cell plays vital role in replacing the cells and tissues for the treatment of conditions such as arthritis, spinal cord injury and Parkinson’s disease. Thus, application of stem cells in treatment of several diseases has eventually boosted the adoption rate. In addition, stem cells allow repairing of injured joints and tissues that improves the body's ability to heal. Further, it also helps to decrease inflammation and prevent scar tissue development.

Growing prevalence of chronic diseases such as skin disorders, cancer and several infectious conditions coupled with rising demand for organ transplant will fuel the market growth in the region. According to the National Cancer Institute, in 2020, over 1.8 million people were diagnosed with cancer in the U.S. The approved regenerative medicines specified for cancer treatment therapy will provide industry expansion opportunities.

Asia Pacific Market, By Type

Cell therapy segment garnered more than 50% Asia Pacific regenerative medicine market revenue share in 2020. Cell therapy is one of the leading techniques that restore the lost function of tissue rather than developing new organ. Growing advancements in cell therapy and rise in prevalence of diseases such as cancer and cardiac abnormalities will drive the segment growth. In addition, continuous research, and advances in stem cell therapy to treat various serious conditions will lead to lucrative segment growth.

Asia Pacific Market, By Country

China will dominate the Asia Pacific regenerative medicine market during the forecast period. Growing research and development by government and different organizations to discover innovative medicines will significantly influence the market growth. Government of China approved various research activities associated to human embryonic stem cells that have helped researchers to discover the clinical potential of embryonic stem cells. Further, rising disposable income and high investment in infrastructure will offer growth opportunities for the market.

Asia Pacific Market, By Application

Musculoskeletal segment revenue will reach USD 6.5 billion by 2027. Growing prevalence of musculoskeletal diseases including rheumatoid arthritis and osteoarthritis will majorly drive the segment size. According to the report published by WHO in 2021, around 1.71 billion people were diagnosed with musculoskeletal conditions globally. In addition, elderly population is prone to musculoskeletal diseases.

Competitive Industry Landscape

Few of the established players involved in Asia Pacific regenerative medicine market include Allergan plc, TERUMO BCT, ORTHOCELL LTD, and Japan Tissue Engineering Co., Ltd., among several others. These strategic players are continuously improving their performance for better outcome and are involved in acquisitions and collaborations to cater to growing patient pool.

 

Frequently Asked Question(FAQ) :

The market size for regenerative medicine in Asia Pacific was surpassed USD 5 billion in 2020 and will grow at around 20.8% CAGR from 2021 to 2027 due to rising preference for advanced therapies for a host of diseases.
Cell therapy held over 50% share of Asia Pacific industry in 2020 and will grow with increasing demand for restoring the lost function of tissue.
Musculoskeletal application could be valued at USD 6.5 billion in Asia Pacific market by 2027 due to rising prevalence of rheumatoid arthritis and osteoarthritis.
The market forecast for regenerative medicine in China will be strong with increasing investment in research and development activities.
ORTHOCELL LTD, Allergan plc, Japan Tissue Engineering Co., Ltd., and TERUMO BCT, among others some of the key players boosting Asia Pacific market share.

Premium Report

Have questions?
  • Inquire Before Buying
  • Why Choose us?

    • on-time delivery On-Time Delivery

      We commit to on-time delivery of reports to keep you ahead.

    • assured quality Assured Quility

      With a wide network of industry experts and trained in-house analysts, we assure best service quality.

    • Custom Research Service

      We offer research services to meet specific client requirements and provide them with actionable insights on target markets.

    • payment security Payment Security

      Our safe payment gateway gives you full control of your personal data, at all times.

    Connect with our sales team

     1-800-986-6917

     [email protected]